Dimerix Courts Investors With Perth and Singapore Briefings on FSGS Phase 3 Program

The latest announcement is out from Dimerix Limited ( (AU:DXB) ).

Dimerix Limited has invited existing and potential investors to attend interactive briefings in Perth on 16 March 2026 and in Singapore on 20 April 2026, where executives will provide updates on the global ACTION3 Phase 3 trial of DMX-200 in FSGS kidney disease. The sessions will also cover the commercial partnering status of DMX-200 and outline the company’s broader growth strategy, giving stakeholders greater visibility into its late-stage development progress and positioning in the rare kidney disease market.

The Perth event will feature a presentation and Q&A with CEO and Managing Director Dr Nina Webster, while the Singapore briefing will include both Dr Webster and COO Dr Rob Shepherd alongside a presentation from Racura Oncology. By engaging investors through these in-person updates, Dimerix aims to strengthen market confidence in its Phase 3 program and commercial pathway, highlighting the potential of DMX-200 to address a serious unmet medical need in FSGS where no targeted therapies are currently approved.

The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.45 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.

More about Dimerix Limited

Dimerix Limited is an Australian biopharmaceutical company focused on developing therapies for kidney diseases, including focal segmental glomerulosclerosis. Its lead asset, DMX-200, is a chemokine receptor CCR2 antagonist administered alongside standard angiotensin II receptor blockers, supported by global patent protection and orphan drug designation in major markets.

Average Trading Volume: 1,261,092

Technical Sentiment Signal: Hold

Current Market Cap: A$264.2M

For an in-depth examination of DXB stock, go to TipRanks’ Overview page.